28.52
-0.19 (-0.66%)
| Previous Close | 28.71 |
| Open | 28.13 |
| Volume | 1,920,400 |
| Avg. Volume (3M) | 1,675,950 |
| Market Cap | 4,533,681,664 |
| Price / Earnings (Forward) | 90.91 |
| Price / Sales | 5.78 |
| Price / Book | 7.37 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | -64.37% |
| Operating Margin (TTM) | -48.91% |
| Diluted EPS (TTM) | -3.04 |
| Quarterly Revenue Growth (YOY) | -30.20% |
| Total Debt/Equity (MRQ) | 332.93% |
| Current Ratio (MRQ) | 8.47 |
| Operating Cash Flow (TTM) | -500.95 M |
| Levered Free Cash Flow (TTM) | -352.83 M |
| Return on Assets (TTM) | -9.91% |
| Return on Equity (TTM) | -93.10% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Ionis Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.75 |
|
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.83% |
| % Held by Institutions | 105.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tweedy, Browne Co Llc | 31 Dec 2024 | 3,248,863 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (RBC Capital, 145.44%) | Buy |
| Median | 52.50 (84.08%) | |
| Low | 39.00 (Redburn Atlantic, 36.75%) | Hold |
| Average | 53.83 (88.75%) | |
| Total | 3 Buy, 3 Hold | |
| Avg. Price @ Call | 32.40 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Redburn Atlantic | 31 Mar 2025 | 39.00 (36.75%) | Hold | 30.17 |
| JP Morgan | 24 Mar 2025 | 45.00 (57.78%) | Hold | 33.45 |
| 11 Mar 2025 | 47.00 (64.80%) | Hold | 33.03 | |
| BMO Capital | 20 Feb 2025 | 45.00 (57.78%) | Hold | 32.69 |
| Citigroup | 20 Feb 2025 | 64.00 (124.40%) | Buy | 32.69 |
| Needham | 20 Feb 2025 | 60.00 (110.38%) | Buy | 32.69 |
| RBC Capital | 20 Feb 2025 | 70.00 (145.44%) | Buy | 32.69 |
| 15 Jan 2025 | 70.00 (145.44%) | Buy | 33.21 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |